Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis

Official title

A Multicenter, Randomized, Double-blind, Parallel-group Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Moderate to Severe Plaque Psoriasis

Overview

This study is a randomized, double-blind, multi-center, parallel, phase II clinical trial, aiming to evaluate the efficacy and safety of SHR-1139 injection for adult patients with psoriasis. The trial includes a 4-week screening period, a 52-week treatment period, and a 12-week safety follow-up period. Approximately 60 patients with psoriasis are expected to participate.

Interventions

• Drug The SHR-1139 injection
  The SHR-1139 injection
• Drug placebo
  placebo

Primary outcome measures

• The proportion of participants who achieved a 100% improvement in the Psoriasis Area and Severity Index (PASI) score compared to the baseline by the 12th week (PASI 100). [Time frame: 12th week]

Secondary outcome measures (4)

• The proportion of participants who achieved a minimum improvement of at least 75% in PASI compared to the baseline (PASI 75) in the 12th week; [Time frame: 12th week]
• The proportion of participants who achieved a minimum improvement of at least 90% in PASI compared to the baseline (PASI 90) in the 12th week [Time frame: 12th week]
• The proportion of participants who achieved a sPGA response of 0 or 1 (sPGA 0/1) as assessed by the static physician in the 12th week [Time frame: 12th week]
• The proportion of participants who achieved a sPGA response of 0 (sPGA 0) in the 12th week [Time frame: 12th week]

Eligibility criteria

Inclusion criteria

• During the screening process, the body mass index (BMI = weight (kg) / height\^2 (m\^2)) was ≥ 18 kg/m\^2;
• History of plaque psoriasis for more than 6 months before randomization；
• The PASI score, sPGA score, and BSA at the screening and baseline required certain requirements;
• Participants suitable for phototherapy or systemic psoriasis treatment for moderate to severe plaque psoriasis;
• Participants voluntarily signed the informed consent before any procedures related to the study, could communicate smoothly with the researchers, understood and were willing to strictly follow the requirements of this clinical study protocol to complete the study;
• Female participants with reproductive capacity or their male partners with reproductive capacity, starting from the date of signing the informed consent until 72 weeks after the last medication, had no plans for pregnancy, sperm donation, or egg donation, and voluntarily took effective contraceptive measures. The pregnancy test results of female participants during the screening period and before random administration should be negative, and must be non-lactating.

Exclusion criteria

\-

The following conditions or diseases must be absent:

• The diagnosed psoriasis at the screening or baseline stage is not chronic plaque-type psoriasis;
• Has drug-induced psoriasis;
• Has other skin problems that the investigator considers would interfere with the assessment of psoriasis;
• Has concurrent other active autoimmune diseases, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis, multiple sclerosis or other central demyelinating diseases, primary Sjögren's syndrome, etc.;

Using the following drugs or participating in clinical studies:

• During the pre-baseline period, other biological agents had been used but did not meet the washout requirements.
• Has used drugs targeting the same target before the screening;
• Has received systemic psoriasis treatment drugs within the specified period before the baseline;
• Has received topical psoriasis treatment drugs within the specified period before the baseline;
• Has received phototherapy within the specified period before the baseline;
• Has participated in any clinical study of drugs or medical devices within 3 months before the baseline or within the drug's half-life period;

Important conditions or underlying diseases that affect safety:

• The participant has a history of lymphocytic proliferative diseases;
• The participant has had any active malignant tumor or history of malignant tumor within the previous 5 years before the screening;
• Has a history of moderate to severe congestive heart failure (NYHA cardiac function classification ≥ III) within 3 months before the screening, has experienced cardiovascular or cerebrovascular events or severe bleeding events, and the investigator considers this participant unsuitable for participating in the clinical study;
• Has had opportunistic infections or immunodeficiency diseases within the previous 6 months before the screening;
• Has had active infections requiring oral anti-infection treatment within 2 weeks before the baseline, or has had severe infections or systemic infections within 4 weeks before the baseline, requires intravenous anti-infection treatment or is hospitalized due to infection, or other chronic, recurrent, active infections that the investigator deems unsuitable for participation in this study;
• Has active tuberculosis (TB) or latent TB infection;
• Has human immunodeficiency virus antibody (HIV) positive at screening, or hepatitis C virus (HCV) antibody positive and further HCV-RNA quantitative positive; or hepatitis B surface antigen (HBsAg) positive; or HBsAg negative but HBcAb positive, and further HBV-DNA test positive; or Treponema pallidum specific antibody positive.
• Has severe, progressive, uncontrolled cardiovascular, liver, kidney, lung, gastrointestinal, hematopoietic system, endocrine, nervous system, mental system (such as depression, suicidal tendency and psychological disorders), skin and mucous membrane diseases, and other conditions that the investigator considers that the patient is not suitable to join this trial;
• Laboratory tests and/or 12-lead electrocardiogram (ECG) results are abnormal at screening:

General situation:

• Pregnant or lactating women;
• Allergic to any component of the test drug;
• Had a history of alcohol abuse or illegal drug use within the previous year before the screening;
• Had blood donation of approximately 500 mL within the previous 8 weeks before randomization or had a blood donation plan during the study;
• Had major surgery within the previous 8 weeks before screening, or had related surgery plans during the study;
• The investigator judges that there are other situations that affect the safety and efficacy evaluation of the test drug.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

China · 1 center

• Dermatology Hospital Hospital of Southern Medical University — Guangzhou

Identifiers

NCT: NCT07719530 · SHR-1139-207

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗